NanoVibronix, Inc. (NASDAQ:NAOV) Short Interest Down 40.9% in April

NanoVibronix, Inc. (NASDAQ:NAOV – Get Rating) was the target of a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 416,000 shares, a decline of 40.9% from the April 15th total of 703,600 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 0.3 days.

Shares of NanoVibronix stock traded up $0.09 during trading on Friday, reaching $0.64. The company’s stock had a trading volume of 879,803 shares, compared to its average volume of 169,576. The company has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.96. NanoVibronix has a fifty-two week low of $0.48 and a fifty-two week high of $4.19.

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in NanoVibronix by 53.7% in the 1st quarter. Vanguard Group Inc. now owns 651,262 shares of the company’s stock valued at $755,000 after buying an additional 227,454 shares during the period. Renaissance Technologies LLC acquired a new position in NanoVibronix in the 4th quarter valued at $361,000. Amtrust Financial Services Inc. increased its stake in NanoVibronix by 69.8% in the 4th quarter. Amtrust Financial Services Inc. now owns 248,148 shares of the company’s stock valued at $258,000 after buying an additional 102,000 shares during the period. Geode Capital Management LLC increased its stake in NanoVibronix by 46.7% in the 3rd quarter. Geode Capital Management LLC now owns 200,752 shares of the company’s stock valued at $413,000 after buying an additional 63,868 shares during the period. Finally, Two Sigma Investments LP acquired a new position in NanoVibronix in the 3rd quarter valued at $333,000. 6.80% of the stock is currently owned by institutional investors and hedge funds.

NanoVibronix Company Profile (Get Rating)

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.

Featured Stories